Serina Therapeutics, Inc.
SERSerina Therapeutics, Inc. (SER) is a biopharmaceutical company focused on developing targeted therapies for rare and severe medical conditions, including hospital-based indications such as opioid-resistant pain. The company aims to leverage its proprietary peptide platform to develop innovative drugs that address unmet medical needs.
Company News
Serina Therapeutics announced that its Chief Development Officer will present data on novel POZ-based lipid nanoparticles (LNPs) that overcome PEG immunogenicity issues. The company's POZ-lipid showed no antibody response in rat vaccine studies, unlike standard PEG-lipids which elicit immune responses. Serina is also advancing replacement ionizab...
Serina Therapeutics, a clinical-stage biotech company, announced that CEO Steve Ledger will present at the 38th Annual Roth Conference on March 24, 2026. The company is developing its proprietary POZ Platformâ„¢ technology for drug optimization, with a focus on treating neurological diseases. Serina has a pipeline including SER-252 (POZ-apomorphi...
U.S. stock futures declined on Friday with major indices down slightly ahead of 'triple witching' expiration. FedEx surged 10.43% on better-than-expected earnings and raised guidance, while Super Micro Computer plunged 23.61% after its co-founder was charged in an alleged AI technology export scheme to China. Planet Labs soared 17.25% and Scholas...
Serina Therapeutics announced the first patient enrollment in its Phase 1b registrational trial of SER-252, an investigational apomorphine therapy for advanced Parkinson's disease. The trial, initiated in Australia, evaluates safety, tolerability, pharmacokinetics, and preliminary efficacy. The company remains on track for first patient dosing in...
Serina Therapeutics' CEO Steven Ledger will present at Tribe Public's webinar on February 4, 2026, discussing FDA initiatives and their impact on drug development. The company recently received FDA clearance for its SER-252 IND application for Parkinson's disease treatment and is initiating Phase 1b clinical activities in Australia.
